[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Parkinson’s Disease Therapeutics Market is Forecast to Show Slow Growth to 2020, According to GlobalData

07 May 2012 • by Natalie Aster

During the period 2002-2011, the global PD therapeutics market grew at a CAGR of 5.8%. The analysis shows that the market size was primarily driven by two key parameters: the increase in PD prevalence due to the increase in the aging population in the 11 key markets and the increasing cost of therapy. The top three drugs in the G7 markets (the US, Japan, Germany, the UK, Spain, France, and Italy) were Stalevo/Comtan, Mirapex, and Azilect with annual sales of $688.2m, $567.8m and $323.5m respectively.

According to the report “Parkinson's Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020” by GlobalData, the global PD therapeutics market is expected to grow at a modest CAGR of 2.2% and is forecast to reach $3,650m by 2020. This modest growth rate is due to the patent expiries of major drugs, the subsequent entry of generics and the weak, late-stage developmental pipeline. The major drugs, which are expected go off patent during this period are Azilect, Comtan, Stalevo, Tasmar, Mirapex ER and Requip XL, of which the impact is expected to be partially adjusted by the introduction of new drugs such as IPX 066, preladenant and safinamide during 2011-2020.

Report Details:

Parkinson's Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020
Published: January, 2012
Pages: 318
Price: US$ 6.995,00

The PD market has unmet need in terms of both efficacy and safety, implying that the market is poorly served by the existing treatment options and that scope exists for new entrants to gain a significant market share.

Based on the safety and efficacy assessment, unmet need in PD therapeutics market is estimated to be high. It suggests that despite the availability of a number of treatment options, there is a need for the new products with increased levels of safety and efficacy. The high unmet need is primarily attributed to the lack of drugs with disease modifying activity able to control disease progression. The currently available therapies only provide symptomatic relief and some drugs are additionally associated with safety issues in long term use.

More information can be found in the report “Parkinson's Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020” by GlobalData.

To order the report or ask for sample pages contact [email protected]


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest